Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LumiraDx
London, United Kingdomlumiradx.com ↗
- Ownership
- Public · LMDX
- Employees
- ~1200
- Development stage
- Commercial
01
Overview
The company’s microfluidic point-of-care diagnostic platform delivers lab-comparable results for a wide range of tests within minutes. Its COVID‑19 antigen test was widely deployed during the pandemic. The platform supports over nine commercialized assays with more than thirty in development or on market for infectious disease, cardiovascular markers like NT-proBNP and D-dimer, diabetes markers such as HbA1c, and others. Clinical studies have demonstrated high sensitivity/specificity for key assays including COVID‑19 antigen testing. As of acquisition by Roche in July 2024 the business had shipped over thirteen thousand instruments to more than sixty countries. The company’s UK entity entered administration following the asset sale.
- Therapeutic areas
- HematologyCardiovascularEndocrinologyInfectious Diseases
- Modalities
- Device (Point-of-care diagnostic platform)Microfluidic technology-based diagnosticsImmunoassay diagnosticsClinical chemistry diagnosticsMolecular diagnostics (future potential as per Roche integration)
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
CVS PharmacyNational Health Service UKBill & Melinda Gates FoundationGovernments and global health organizations during pandemic response
03
Financials
- Market cap
- $5.1M
- Total revenue
- $21M
- Enterprise value
- $382.5M
Beyond the preview
Go deeper on LumiraDx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LumiraDx.